Kurma investor builds stake as French VC looks to crossover deals

Like several of its peers in the U.S. and Europe, early stage investor Kurma is among a handful of venture firms that are committing more capital to support biotechs in the growth stage, reflecting an increasing desire for VCs to maintain larger stakes as private companies’ valuations swell.

France-based Kurma Partners is targeting the €200-€300 million range for a new Growth Opportunity fund that will invest in biopharmas around the time of clinical proof of concept or as they approach the public equity markets, as well as diagnostics companies seeking to enter the commercial stage, the firm’s Rémi Droller told BioCentury...